Target intelligence / Profile preview

E3 ubiquitin-protein ligase SIAH1 (SIAH1) (SIAH1)

Target
SIAH1
Molecular classification
E3 ubiquitin-protein ligase, RING-finger protein, Enzyme
01

Overview

E3 ubiquitin-protein ligase SIAH1 (SIAH1) is a member of the Seven in absentia homolog family, characterized by an N-terminal RING finger domain that confers E3 ligase activity. It plays a pivotal role in the ubiquitin-proteasome system by targeting a wide array of substrates—including beta-catenin, DCC, and alpha-synuclein—for degradation (UniProt Q8IUQ4). SIAH1 is deeply involved in regulating cellular processes such as apoptosis, DNA damage response, and hypoxia signaling (PubMed: 15103331). In oncology, it frequently functions as a tumor suppressor by downregulating pro-proliferative signaling pathways, though its depletion or overexpression is linked to various malignancies (PubMed: 11585923). Furthermore, SIAH1 is implicated in neurodegeneration, specifically in the pathogenesis of Parkinson's disease, where it promotes the ubiquitination and aggregation of alpha-synuclein (PubMed: 15630441). Therapeutic interest in SIAH1 focuses on its potential as a target for small molecule inhibitors or as a component in targeted protein degradation strategies.

Other names
Seven in absentia homolog 1Siah-1HUMSIAHSiah-1aSiah-1 protein
02

Mechanism of action

E3 ubiquitin ligase activity facilitating the transfer of ubiquitin from an E2 enzyme to specific substrate proteins, marking them for 26S proteasomal degradation.

03

Biological functions

UbiquitinationApoptosisSignal transductionCell cycle regulationProtein degradationDNA damage responseHypoxia response
04

Disease associations

CancerNeurodegenerative diseaseParkinson's diseaseLewy body dementiaInflammation
05

Safety considerations

Potential for broad off-target effects due to multiple substratesDisruption of essential apoptotic pathwaysContext-dependent role in tumor progression (tumor suppressor vs. promoter)Potential interference with normal DNA damage repair mechanisms
06

Interacting drugs

Menadione

1 more in the full profile.

07

Biomarkers

SIAH1 expression levelNuclear SIAH1 localizationBeta-catenin levelsAlpha-synuclein ubiquitination status

Beyond the preview

Go deeper on E3 ubiquitin-protein ligase SIAH1 (SIAH1) (SIAH1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on E3 ubiquitin-protein ligase SIAH1 (SIAH1) (SIAH1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call